Ubs Group Ag Arvinas, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Arvinas, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 471,578 shares of ARVN stock, worth $10.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

471,578

Previous 256,359 83.95%

Holding current value

$10.7 Million

Previous $6.82 Million 70.19%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$23.66 - $32.73 $5.09 Million - $7.04 Million	215,219 Added 83.95%	471,578 $11.6 Million
Q2 2024 Aug 13, 2024	SELL	$24.46 - $40.4 $921,775 - $1.52 Million	-37,685 Reduced 12.82%	256,359 $6.82 Million
Q1 2024 May 13, 2024	BUY	$36.38 - $52.31 $1.35 Million - $1.94 Million	37,058 Added 14.42%	294,044 $12.1 Million
Q4 2023 Feb 09, 2024	SELL	$14.19 - $42.33 $890,450 - $2.66 Million	-62,752 Reduced 19.63%	256,986 $10.6 Million
Q3 2023 Nov 09, 2023	SELL	$19.64 - $28.21 $1.13 Million - $1.63 Million	-57,778 Reduced 15.3%	319,738 $6.28 Million
Q2 2023 Aug 11, 2023	SELL	$21.73 - $31.43 $478,994 - $692,811	-22,043 Reduced 5.52%	377,516 $9.37 Million
Q1 2023 May 12, 2023	BUY	$26.15 - $37.26 $1.88 Million - $2.68 Million	71,920 Added 21.95%	399,559 $10.9 Million
Q4 2022 Feb 08, 2023	BUY	$32.47 - $57.24 $991,406 - $1.75 Million	30,533 Added 10.28%	327,639 $11.2 Million
Q3 2022 Nov 10, 2022	SELL	$41.87 - $57.99 $719,787 - $996,906	-17,191 Reduced 5.47%	297,106 $13.2 Million
Q2 2022 Aug 10, 2022	SELL	$36.01 - $74.24 $3.56 Million - $7.33 Million	-98,730 Reduced 23.9%	314,297 $13.2 Million
Q1 2022 May 16, 2022	BUY	$60.27 - $81.57 $7.63 Million - $10.3 Million	126,540 Added 44.17%	413,027 $27.8 Million
Q4 2021 Feb 14, 2022	BUY	$65.85 - $96.21 $9.44 Million - $13.8 Million	143,289 Added 100.06%	286,487 $23.5 Million
Q3 2021 Nov 15, 2021	BUY	$73.2 - $107.87 $5.66 Million - $8.34 Million	77,270 Added 117.2%	143,198 $11.8 Million
Q2 2021 Aug 13, 2021	BUY	$60.45 - $84.26 $3.87 Million - $5.4 Million	64,065 Added 3438.81%	65,928 $5.08 Million
Q1 2021 May 12, 2021	SELL	$58.19 - $91.37 $787,077 - $1.24 Million	-13,526 Reduced 87.89%	1,863 $123,000
Q4 2020 Feb 11, 2021	BUY	$20.19 - $84.93 $261,743 - $1.1 Million	12,964 Added 534.6%	15,389 $1.31 Million
Q3 2020 Nov 12, 2020	SELL	$22.99 - $36.34 $487,525 - $770,626	-21,206 Reduced 89.74%	2,425 $58,000
Q2 2020 Jul 31, 2020	BUY	$29.88 - $56.74 $293,302 - $556,959	9,816 Added 71.05%	23,631 $793,000
Q1 2020 May 01, 2020	SELL	$33.0 - $54.5 $1.14 Million - $1.89 Million	-34,651 Reduced 71.5%	13,815 $557,000
Q4 2019 Feb 14, 2020	SELL	$15.39 - $44.38 $223,585 - $644,752	-14,528 Reduced 23.06%	48,466 $1.99 Million
Q3 2019 Nov 14, 2019	BUY	$21.55 - $27.61 $614,649 - $787,492	28,522 Added 82.74%	62,994 $1.36 Million
Q2 2019 Aug 14, 2019	BUY	$15.96 - $23.8 $65,914 - $98,294	4,130 Added 13.61%	34,472 $758,000
Q1 2019 May 14, 2019	BUY	$13.55 - $23.79 $352,218 - $618,397	25,994 Added 597.84%	30,342 $447,000
Q4 2018 Feb 14, 2019	BUY	$11.19 - $18.56 $48,654 - $80,698	4,348 New	4,348 $56,000

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.21B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account